Looking for virtuous promiscuity: electrocardiographic evidence of multichannel drug block.
The finding of QTc prolongation often sounds the death knell for a new molecule, but investigators have long suspected that QTc prolongation alone may be an indifferent predictor of risk. Premature or inappropriate rejection of promising molecules deprives clinicians of new therapies and depletes industry resources. Could it be that the conventional electrocardiogram contains information that might prevent us from relegating "virtuous" compounds to a fate they do not deserve?